Intravenous saline control, in a double-blind, crossover study, with infusion days at least 2 weeks apart.

40 mg citalopram in 250 ml saline infused over 1 hour, in a double-blind, crossover study, with infusion days at least 2 weeks apart.

Alcohol Dependent

participants with no Axis I illness or substance use disorder

Healthy Control

Total

Sex: Female, Male

Race/Ethnicity, Customized

Region of Enrollment

To assess whether craving for alcohol in alcohol dependence is affected by iv citalopram, compared to placebo.
Cue-induced craving for alcohol was assessed using the Alcohol Urge Questionnaire, composed of 8 questions with responses on a 0 (none) to 7 (severe or highest level) which when scored provide an estimate of the level of craving for alcohol for the participant. A maximum score is thus 56, indicating the highest level of craving for alcohol, whereas the minimum score of 0 indicates no appreciable craving for alcohol.

40 mg citalopram in 250 ml saline infused over 1 hour, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
citalopram: citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.

Alcohol Dependent Citalopram Infusion

Intravenous saline control, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
citalopram: citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.

Alcohol Dependent Placebo

Healthy Control Citalopram Infusion

Healthy Control Placebo Infusion

Craving for Alcohol in Alcohol Dependence With Citalopram Compared to Placebo

relative binding potential of dopamine D2/3 receptor specific tracer compared to cerebellum, where there is known to be almost no dopamine receptors.

Alcohol Dependent Placebo Infusion

Striatal Dopamine Receptor Availability in Alcohol Dependence With Citalopram, Compared to Placebo

DSM-IV alcohol dependent participants.
Qualifying participants were invited back for three subsequent visits: a structural MRI scan, and two study medication/[18F]-fallypride PET scanning days (citalopram 40 mg iv, or saline placebo, double-blinded, administered in counter-balancing order) more than 1 week apart. All completing participants had breathalyzer-confirmed exhaled alcohol concentration of 0, and low alcohol withdrawal scores (confirming no intoxication and minimal alcohol withdrawal symptoms) on all study visits (see below). On study medication/PET scanning days, the following procedures were completed in order: 1. Breathalyzer, withdrawal, and psychiatric symptomatology screening; 2. Intravenous citalopram (or saline placebo) infusion (1 h). 3. Cue-induced craving assessment (~20 minutes). 4. [18F]-fallypride PET scanning (~3 h).

Alcohol Dependent Citalopram First Placebo Second

Alcohol Dependent Placebo First Citalopram Second

participants with no Axis I mental illness or substance use disorder.
Same procedures as AD group

Healthy Control Citalopram First Placebo Second

Healthy Control Placebo First Citalopram Second

Overall Study

Todd Zorick

Placebo

Citalopram Infusion

Alcohol Dependence

citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.

citalopram

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics

VA Office of Research and Development

Alcoholism

Outpatient detoxification program

BEAUJON Hospital

Outpatient Versus Inpatient Detoxification Program for Alcohol Dependent Patients Seeking Abstinence: The IN/OUT Study

Comparison of Efficacy of an Outpatient vs Inpatient Detoxification Program for Alcohol Dependent Patients Seeking Abstinence. A Prospective Randomized Clinical Trial.

alcohol withdrawal delirium/− nicotin

Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics

Outpatient Versus Inpatient Detoxification Program for Alcohol Dependent Patients Seeking Abstinence: The IN/OUT Study

Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird